Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Impact in
- Oncology 320
Classified as
- Journal
- Nature Medicine
In The Last Decade
doi.org/10.1038/nm.4040 →Countries where authors are citing Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
This map shows the geographic impact of Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition more than expected).
Fields of papers citing Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
This network shows the impact of Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
About Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
This paper, published in 2016, received 775 indexed citations . Written by Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, María Gomez‐Caraballo, Faria M. Siddiqui, Hillary E. Mulvey, Yosef E. Maruvka, Fei Ji, Hyo-Eun Carrie Bhang and Giulia Siravegna covering the research area of Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. It is primarily cited by scholars working on Molecular Biology (416 citations), Oncology (320 citations), Pulmonary and Respiratory Medicine (301 citations), Cancer Research (275 citations) and Cell Biology (47 citations). Published in Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1038/nm.4040.